menu
    • menu
    [{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.55000000000000004,"dosageForm":"Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0.53000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0.55000000000000004,"dosageForm":"Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Ironshore Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Collegium Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ironshore Pharmaceuticals \/ Collegium Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Ironshore Pharmaceuticals

    Menu

    Ironshore Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Collegium Pharmaceutical

                            Deal Size : $550.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

                            Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.

                            Product Name : Jornay PM

                            Product Type : Other Small Molecule

                            Upfront Cash : $525.0 million

                            July 29, 2024

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Collegium Pharmaceutical

                            Deal Size : $550.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Collegium Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years with ADHD

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 28, 2024

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Collegium Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Collegium Pharmaceutical

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Collegium Completes Acquisition of Ironshore Therapeutics

                            Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.

                            Product Name : Jornay PM

                            Product Type : Other Small Molecule

                            Upfront Cash : $525.0 million

                            April 09, 2024

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Collegium Pharmaceutical

                            Deal Size : $525.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ironshore to Present a Dose Conversion Poster at the 2020 American Society of Clinical Psychopharmacology Virt...

                            Details : The data presented in the poster may help guide clinicians to target an appropriate dose range of JORNAY PM extended-release capsules CII, which was approved in August 2018 by the U.S. FDA for the treatment of ADHD in patients 6 years and older.

                            Product Name : Jornay PM

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 06, 2020

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLD100

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADH...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 31, 2016

                            Lead Product(s) : HLD100

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 11, 2015

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 10, 2015

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLD200

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            October 02, 2014

                            Lead Product(s) : HLD200

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 24, 2013

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed

                            Ironshore Pharmaceuticals

                            U.S.A arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HLD100

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Releas...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 26, 2013

                            Lead Product(s) : HLD100

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth